Search - tctmd.com

Displaying 41 - 58 of 58

Sort: Relevancy | Date

News Daily News

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Shelley Wood

February 26, 2020

News Daily News

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

Michael O'Riordan

January 17, 2020

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

FDA Approves Two Generic Versions of Apixaban

Todd Neale

December 23, 2019

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

L.A. McKeown

October 21, 2019

News Daily News

FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients

Yael L. Maxwell

May 16, 2019

News Daily News

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

Michael O'Riordan

May 06, 2019

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Daily News

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

Shelley Wood

December 18, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

Todd Neale

October 12, 2018

News Daily News

High-Risk Medical Device Approval Process in Europe Inches Towards Transparency

Michael O'Riordan

July 20, 2018

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Daily News

Betrixaban Approved for Prevention of VTE

Michael O'Riordan

June 23, 2017

News Daily News

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Michael O'Riordan

August 18, 2016

Advertisement

FDA Approves New Lipid-Lowering Drug, Bempedoic Acid

Injectable GLP-1 Agonist Semaglutide Gets CVD Event Reduction Indication

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

FDA Approves Two Generic Versions of Apixaban

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

FDA Approves Dalteparin Sodium as First Anticoagulant For Use in Pediatric VTE Patients

Tafamidis Approved for Treatment of Transthyretin Amyloid Cardiomyopathy

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

TCTMD’s Top 10 Most Popular Stories for January 2019

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

High-Risk Medical Device Approval Process in Europe Inches Towards Transparency

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Betrixaban Approved for Prevention of VTE

FDA Declines to Approve Portola’s Reversal Agent for Factor Xa Inhibitors

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content